Article Text

Download PDFPDF
Novel prognostic predictor of brain atrophy in multiple sclerosis
  1. Hirofumi Ochi
  1. Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon 791-0295, Japan
  1. Correspondence to Dr Hirofumi Ochi, Department of Neurology and Geriatric Medicine, Ehime University Graduate School of Medicine, Toon 791-0295, Japan; hochi{at}m.ehime-u.ac.jp

Statistics from Altmetric.com

Short-term practice effects on cognitive tests predict future brain atrophy progressionand treatment response to fingolimod in multiple sclerosis

Cognitive impairment occurs in more than half of patients with multiple sclerosis (MS) and is a leading cause of disability.1 The Paced Auditory Serial Addition Test (PASAT) is part of the Multiple Sclerosis Functional Composite (MSFC) and has been widely used in clinical research to assess cognitive status of patients with MS because it is a sensitive assessment of information processing speed, attention and working memory, which are the cognitive domains most frequently affected in MS. However, repeated exposures to the PASAT can lead to improvements in performance, which is referred to as practice effects. Since practice effects are most evident for the PASAT among three measures of …

View Full Text

Footnotes

  • Contributors HO is the sole contributor of this editorial commentary.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles